

**REMARKS**

Reconsideration is respectfully requested.

In response to the election of species requirement:

With respect to the therapeutic entity X, Applicant elects an antiproliferative drug, with traverse. Support in the description is found on page 16, line 14; support for targeting neoplastic cells is given on page 13, line 11.

With respect to the *in vivo* cleavable linking entity Y, Applicants elect an *in vivo* enzymatically cleavable linking entity, with traverse. Support in the description is found on page 12, lines 18-20 and lines 23-26.

With respect to the chemically reactive group Z, Applicants elect a chemically reactive group for reacting *in vivo* with a thiol reactive functionality on albumin so as to form a covalent bond therewith, with traverse. Support in the description is found on page 4, lines 7, 14, 17 and 27, and page 8, line 17.

Applicants respectfully note that the pending claims are directed to platform technology, specifically any therapeutic compound of the formula X-Y-Z, wherein X is a therapeutic entity, Y is an *in vivo* cleavable linking entity covalently connecting said therapeutic entity to Z, and Z is a chemically reactive group for reacting *in vivo* with a reactive functionality on an endogenous vascular or blood component protein so as to form a covalent bond therewith. Since the invention is directed to platform technology, each of X, Y, and Z should not be limited to individual embodiments of each X, Y, and Z.

Applicants request examination of the claims on the merits.

Applicant's election is made without prejudice. As noted by the Examiner, upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional

species, provided that all claims to each additional species are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141.

### **Information Disclosure Statement**

Applicants are submitting herewith a Third Supplemental Information Disclosure Statement and an attached Form PTO-1449. Copies of the documents are also submitted therewith. The Examiner is requested to make those documents of record.

### **Conclusion**

An action on the merits of all the claims and a Notice of Allowance thereof are respectfully requested.

Dated: October 23, 2003

Respectfully submitted,

By Michael R. Ward  
Michael R. Ward

Registration No.: 38,651  
MORRISON & FOERSTER LLP  
425 Market Street  
San Francisco, California 94105  
(415) 268-6237